Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
Top Cited Papers
- 7 January 2021
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 384 (1), 20-30
- https://doi.org/10.1056/nejmoa2030340
Abstract
The Journal recently published two trials of tocilizumab for coronavirus disease 2019 (Covid-19) (Dec. 10 and Jan. 7 issues).1,2 According to the articles, the primary outcome in both trials was mechanical ventilation or death. However, there are important discrepancies between those articles and the trial protocols and registry information.Funding Information
- Genentech
This publication has 35 references indexed in Scilit:
- Africa in the Path of Covid-19New England Journal of Medicine, 2020
- Clinical characteristics of 3062 COVID‐19 patients: A meta‐analysisJournal of Medical Virology, 2020
- Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City AreaJAMA, 2020
- The Toughest Triage — Allocating Ventilators in a PandemicNew England Journal of Medicine, 2020
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020
- COVID-19: consider cytokine storm syndromes and immunosuppressionThe Lancet, 2020
- Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, ChinaIntensive Care Medicine, 2020
- The Novel Coronavirus Originating in Wuhan, ChinaJAMA, 2020
- Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndromeExpert Review of Clinical Immunology, 2019